Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis

E Balsells, L Guillot, H Nair, MH Kyaw - PloS one, 2017 - journals.plos.org
Background Routine immunisation with pneumococcal conjugate vaccines (PCV7/10/13)
has reduced invasive pneumococcal disease (IPD) due to vaccine serotypes significantly …

The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious …

JS Bradley, CL Byington, SS Shah… - Clinical infectious …, 2011 - academic.oup.com
Evidenced-based guidelines for management of infants and children with community-
acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and …

Serotype replacement in disease after pneumococcal vaccination

DM Weinberger, R Malley, M Lipsitch - The Lancet, 2011 - thelancet.com
Vaccination with heptavalent pneumococcal conjugate vaccine (PCV7) has significantly
reduced the burden of pneumococcal disease and has had an important public health …

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

T Pilishvili, C Lexau, MM Farley, J Hadler… - The Journal of …, 2010 - academic.oup.com
Background Changes in invasive pneumococcal disease (IPD) incidence were evaluated
after 7 years of 7-valent pneumococcal conjugate vaccine (PCV7) use in US children …

Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites

DR Feikin, EW Kagucia, JD Loo, R Link-Gelles… - PLoS …, 2013 - journals.plos.org
Background Vaccine-serotype (VT) invasive pneumococcal disease (IPD) rates declined
substantially following introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into …

[HTML][HTML] Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal …

JP Nuorti, CG Whitney - 2010 - cdc.gov
SUMMARY On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein
conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer …

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 …

LA Hicks, LH Harrison, B Flannery… - The Journal of …, 2007 - academic.oup.com
Background. Widespread use of pneumococcal conjugate vaccine (PCV7) resulted in
decreases in invasive disease among children and elderly persons. The benefits may be …

Emergence of parapneumonic empyema in the USA

CG Grijalva, Y Zhu, JP Nuorti, MR Griffin - Thorax, 2011 - thorax.bmj.com
Background Although recent reports suggest that the incidence of parapneumonic empyema
has increased in several regions of the USA, national trends in disease burden are …

Population Snapshot of Emergent Streptococcus pneumoniae Serotype 19A in the United States, 2005

MR Moore, RE Gertz, Jr, RL Woodbury… - The Journal of …, 2008 - academic.oup.com
Background Serotype 19A invasive pneumococcal disease (IPD) increased annually in the
United States after the introduction of the 7-valent conjugate vaccine (PCV7). To understand …

New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine

JR Casey, DG Adlowitz… - The Pediatric infectious …, 2010 - journals.lww.com
Objective: To describe NP and AOM otopathogens during the time frame 2007 to 2009, 6 to
8 years after the introduction of 7-valent pneumococcal conjugate (PCV7) in the United …